Nuveen Asset Management, LLC Ligand Pharmaceuticals Inc Transaction History

Nuveen Asset Management, LLC

$334 Billion
Q2 2024

A detailed history of Nuveen Asset Management, LLC transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 43,815 shares of LGND stock, worth $4.45 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

43,815

Previous 43,037 1.81%

Holding current value

$4.45 Million

Previous $3.15 Million 17.32%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$68.53 - $87.91 $53,316 - $68,393	778 Added 1.81%	43,815 $3.69 Million
Q4 2023 Feb 14, 2024	BUY	$49.57 - $72.63 $18,440 - $27,018	372 Added 0.87%	43,037 $3.07 Million
Q3 2023 Nov 14, 2023	SELL	$58.86 - $72.67 $2.49 Million - $3.07 Million	-42,314 Reduced 49.79%	42,665 $2.56 Million
Q2 2023 Aug 14, 2023	BUY	$69.53 - $79.33 $1.41 Million - $1.61 Million	20,349 Added 31.49%	84,979 $6.13 Million
Q1 2023 May 15, 2023	BUY	$65.67 - $77.08 $1.29 Million - $1.51 Million	19,636 Added 43.64%	64,630 $4.75 Million
Q4 2022 Feb 14, 2023	SELL	$61.72 - $96.74 $426,114 - $667,892	-6,904 Reduced 13.3%	44,994 $3.01 Million
Q3 2022 Nov 14, 2022	SELL	$0.01 - $107.56 $14 - $152,950	-1,422 Reduced 2.67%	51,898 $4.47 Million
Q2 2022 Aug 15, 2022	SELL	$74.52 - $117.06 $63,192 - $99,266	-848 Reduced 1.57%	53,320 $4.76 Million
Q1 2022 May 16, 2022	SELL	$94.99 - $151.56 $121,302 - $193,542	-1,277 Reduced 2.3%	54,168 $6.11 Million
Q4 2021 Feb 14, 2022	SELL	$127.69 - $165.85 $540,384 - $701,877	-4,232 Reduced 7.09%	55,445 $7.71 Million
Q3 2021 Nov 12, 2021	SELL	$102.33 - $144.73 $3.6 Million - $5.09 Million	-35,194 Reduced 37.1%	59,677 $8.64 Million
Q2 2021 Aug 16, 2021	SELL	$113.03 - $155.64 $225,155 - $310,034	-1,992 Reduced 2.06%	94,871 $12.4 Million
Q1 2021 May 17, 2021	BUY	$99.52 - $215.83 $2.76 Million - $5.98 Million	27,726 Added 40.1%	96,863 $14.8 Million
Q4 2020 May 17, 2021	SELL	$80.55 - $106.05 $824,509 - $1.09 Million	-10,236 Reduced 12.9%	69,137 $6.88 Million
Q4 2020 Feb 16, 2021	BUY	$80.55 - $106.05 $661,718 - $871,200	8,215 Added 11.54%	79,373 $7.89 Million
Q3 2020 Nov 16, 2020	SELL	$89.56 - $126.72 $221,302 - $313,125	-2,471 Reduced 3.36%	71,158 $6.78 Million
Q2 2020 Aug 14, 2020	SELL	$68.28 - $123.65 $3.06 Million - $5.54 Million	-44,766 Reduced 37.81%	73,629 $8.24 Million
Q1 2020 May 14, 2020	BUY	$63.37 - $107.88 $550,051 - $936,398	8,680 Added 7.91%	118,395 $8.61 Million
Q4 2019 Feb 14, 2020	SELL	$96.94 - $113.59 $445,342 - $521,832	-4,594 Reduced 4.02%	109,715 $11.4 Million
Q3 2019 Nov 14, 2019	SELL	$86.25 - $120.16 $24,753 - $34,485	-287 Reduced 0.25%	114,309 $11.4 Million
Q2 2019 Aug 15, 2019	BUY	$107.38 - $129.34 $12.3 Million - $14.8 Million	114,596 New	114,596 $13.1 Million
Q1 2019 May 14, 2019	SELL	$105.93 - $142.47 $1.16 Million - $1.57 Million	-10,995 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$128.36 - $272.13 $61,997 - $131,438	-483 Reduced 4.21%	10,995 $1.49 Million
Q3 2018 Nov 13, 2018	SELL	$211.18 - $274.49 $116,149 - $150,969	-550 Reduced 4.57%	11,478 $3.15 Million
Q2 2018 Aug 14, 2018	BUY	$150.77 - $207.98 $260,229 - $358,973	1,726 Added 16.75%	12,028 $2.49 Million
Q1 2018 May 14, 2018	BUY	$138.63 - $182.62 $145,700 - $191,933	1,051 Added 11.36%	10,302 $1.7 Million
Q4 2017 Feb 14, 2018	SELL	$128.36 - $147.04 $30,934 - $35,436	-241 Reduced 2.54%	9,251 $0
Q3 2017 Nov 14, 2017	BUY	$120.91 - $137.94 $1.15 Million - $1.31 Million	9,492	9,492 $1.29 Million

Others Institutions Holding LGND

# of Institutions

247

Shares Held

17.5M

Call Options Held

61K

Put Options Held

7.8K

View Full List

About LIGAND PHARMACEUTICALS INC

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.72B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

More about LGND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account

Nuveen Asset Management, LLC Ligand Pharmaceuticals Inc Transaction History